

Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy (A-SEEDS Co., Ltd.)



City	Year of Establishment	Founder
Matsumoto, Nagano	2020	Yozo Nakazawa

Partner VC	Latest round of Fundraising	Valuation
-	Series A	Non-Disclosure

Contact Information :
tel : 0263-31-5882
e-mail : kiyohito.tani@a-seeds.co.jp

Website : <https://www.a-seeds.co.jp/en-home>

○ Business Plan
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.

○ Research Outline
The objective of this project is to develop large-scale manufacturing technology for CAR-T cell therapy, a novel approach to cancer treatment, utilizing non-viral gene editing methods. Additionally, we aim to establish a robust manufacturing infrastructure through collaboration with domestic and international formulation development and manufacturing support companies, with a view toward conducting global clinical trials and obtaining regulatory approval, while also validating the technology internationally.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2025～2026FY	JPY 920 million	Australia

○International collaborative technology demonstration
- With a view to global expansion, we transfer basic technologies to CDMOs and collaborate with CDMOs to establish mass production methods and supply chains
- Global CRO and we conduct clinical trials to demonstrate the technology